Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo

(2014) L. Sabbagh et al.   JOURNAL OF IMMUNOLOGY

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy

(2013) Amy E Moran et al.   CURRENT OPINION IN IMMUNOLOGY

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

(2013) Michael A. Curran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

(2013) S. R. Goding et al.   JOURNAL OF IMMUNOLOGY

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

Immunotherapy of Cancer with 4-1BB

(2012) D. S. Vinay et al.   MOLECULAR CANCER THERAPEUTICS

Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection

(2012) M. A. Paley et al.   SCIENCE

A molecular profile of T-cell exhaustion in cancer

(2012) Daniel E. Speiser   OncoImmunology

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy

(2011) Laura M. Snell et al.   IMMUNOLOGICAL REVIEWS

4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection

(2011) V. Vezys et al.   JOURNAL OF IMMUNOLOGY

CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation

(2011) H. Z. Qui et al.   JOURNAL OF IMMUNOLOGY

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function

(2011) Jessica Ann Hernandez-Chacon et al.   JOURNAL OF IMMUNOTHERAPY

Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection

(2011) Charlly Kao et al.   NATURE IMMUNOLOGY

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

(2011) Michael A. Curran et al.   PLoS One

T-bet and Eomesodermin Are Required for T Cell-Mediated Antitumor Immune Responses

(2010) Y. Zhu et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche

(2010) A. Banerjee et al.   JOURNAL OF IMMUNOLOGY

Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice

(2010) Gloria H. Y. Lin et al.   PLoS One

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

KLRG1—more than a marker for T cell senescence

(2009) Sian M. Henson et al.   AGE

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

(2009) R. Houot et al.   BLOOD

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists

(2009) K. S. Peggs et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD152 (CTLA-4) regulates effector functions of CD8+T lymphocytes by repressing Eomesodermin

(2009) Johannes K. Hegel et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Immune regulation by 4-1BB and 4-1BBL: complexities and challenges

(2009) Chao Wang et al.   IMMUNOLOGICAL REVIEWS

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

(2009) Y. H. Kim et al.   MOLECULAR CANCER THERAPEUTICS

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer

(2008) David H. Lynch   IMMUNOLOGICAL REVIEWS

Anomalous Type 17 Response to Viral Infection by CD8+ T Cells Lacking T-bet and Eomesodermin

(2008) A. M. Intlekofer et al.   SCIENCE